303 related articles for article (PubMed ID: 15562376)
21. Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
Zanchi A; Tappy L; Lê KA; Bortolotti M; Theumann N; Halabi G; Gauthier T; Mathieu C; Tremblay S; Bertrand PC; Burnier M; Teta D
PLoS One; 2014; 9(10):e109134. PubMed ID: 25330088
[TBL] [Abstract][Full Text] [Related]
22. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
23. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
[TBL] [Abstract][Full Text] [Related]
24. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
25. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
van der Meer RW; Rijzewijk LJ; de Jong HW; Lamb HJ; Lubberink M; Romijn JA; Bax JJ; de Roos A; Kamp O; Paulus WJ; Heine RJ; Lammertsma AA; Smit JW; Diamant M
Circulation; 2009 Apr; 119(15):2069-77. PubMed ID: 19349323
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
[TBL] [Abstract][Full Text] [Related]
27. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Gupta AK; Smith SR; Greenway FL; Bray GA
Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
[TBL] [Abstract][Full Text] [Related]
28. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
[TBL] [Abstract][Full Text] [Related]
29. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
30. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
32. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.
Berria R; Glass L; Mahankali A; Miyazaki Y; Monroy A; De Filippis E; Cusi K; Cersosimo E; Defronzo RA; Gastaldelli A
Clin Pharmacol Ther; 2007 Sep; 82(3):275-81. PubMed ID: 17361126
[TBL] [Abstract][Full Text] [Related]
33. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study.
Wallace TM; Levy JC; Matthews DR
Diabet Med; 2004 Jun; 21(6):568-76. PubMed ID: 15154941
[TBL] [Abstract][Full Text] [Related]
34. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.
Harder H; Nielsen L; Tu DT; Astrup A
Diabetes Care; 2004 Aug; 27(8):1915-21. PubMed ID: 15277417
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
36. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.
Bogacka I; Xie H; Bray GA; Smith SR
Diabetes Care; 2004 Jul; 27(7):1660-7. PubMed ID: 15220243
[TBL] [Abstract][Full Text] [Related]
37. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
39. Impact of pioglitazone on bone mineral density and bone marrow fat content.
Pop LM; Lingvay I; Yuan Q; Li X; Adams-Huet B; Maalouf NM
Osteoporos Int; 2017 Nov; 28(11):3261-3269. PubMed ID: 28735463
[TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
